GlassScriptPhysician profile
Taylor Veh
NPI 1649620964
$2,245.40
in general payments reported to CMS, 2019-2025
27 companies · $428 in 2025
The $428 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $213 · 2021: $260 · 2022: $450 · 2023: $567 · 2024: $328 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,152 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.63 |
| Education | $170.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $347.61 | 2021-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $316.68 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $164.48 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $153.68 | 2023-2025 | Myfembree |
| Gynesonics, INC. | $127.40 | 2020 | |
| Hologic Sales and Service, LLC | $124.58 | 2022-2025 | Third Wave, Thinprep 2000 Processor, Aptima |
| Amgen INC. | $113.33 | 2020-2024 | Prolia, Evenity |
| Evofem Biosciences, INC. | $89.87 | 2021-2025 | Solosec, Phexx, Phexxi |
| Exeltis, USA INC. | $87.32 | 2021-2025 | Slynd |
| Meditrina | $84.86 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.53 | 2020-2025 | |
| Novo Nordisk INC | $73.98 | 2023-2025 | Wegovy |
| Myovant Sciences INC. | $70.12 | 2021-2022 | |
| Millicent US INC | $53.28 | 2025 | Femlyv |
| Myriad Women'S Health, INC. | $51.63 | 2023 | Myrisk |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $51.29 | 2022 | |
| Therapeuticsmd, INC. | $46.80 | 2020-2022 | |
| Aspira Women'S Health INC | $44.91 | 2021-2024 | Ova1 |
| Pfizer INC. | $27.05 | 2022-2023 | |
| Avion Pharmaceuticals | $24.65 | 2023 | Balcoltra |
| Sage Therapeutics, LLC | $22.24 | 2025 | Zurzuvae |
| Radius Health, INC. | $19.84 | 2025 | Tymlos |
| Medtronic, INC. | $17.38 | 2023 | Truclear |
| Minerva Surgical, INC | $15.01 | 2025 | |
| Agile Therapeutics, INC. | $11.89 | 2021 | |
| Lupin INC. | $11.02 | 2020 | |
| Organon LLC | $10.97 | 2025 | Jada System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Veh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.